



Altimune Announces Participation in Vaccine Development Panel at the Annual Regional Biotech Forum

Gaithersburg, Maryland – April 13, 2016 - Altimune, Inc., a clinical stage immunotherapeutic company, today announced that Bill Enright, Chief Executive Officer, will participate in a vaccine development panel at the Annual Regional Biotech Forum. The panel will take place in Gaithersburg, MD on April 19, 2016 at 9:30 AM ET.

The panel, titled “Advancements in Vaccine Development,” will be moderated by Dr. Ripley Ballou, Vice President & Head of Global Vaccines at GlaxoSmithKline. Mr. Enright will discuss Altimune’s innovative approaches to vaccine development and how vaccine development is leading the way in the regional push to become the third largest biotech cluster in the United States.

About Altimune

Altimune is a clinical stage immunotherapeutic company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. Using these technologies, Altimune has developed three novel clinical stage product candidates that potentially represent an entirely new approach to harnessing the immune system.

The Company’s most advanced product candidate, NasoVAX, is a Phase 2-ready intranasally-delivered recombinant influenza vaccine offering broad and rapid protection with potential for significant advantages over traditional flu vaccines. The second most advanced product candidate, HepTcell, is being tested as an immunotherapy for patients chronically infected with hepatitis B and has the potential to provide a functional cure. With the support of the U.S. Biomedical Advanced Research and Development Authority, or BARDA, the Company is developing a third product candidate, NasoShield, a first-in-class anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. The Company intends to leverage the RespirVec and Densigen platforms to develop additional product candidates for a variety of indications.

Contacts:

Bill Enright
President and CEO
Phone: 240-654-1450
Email: enright@altimmune.com

Investor Relations
Stephanie Carrington
ICR, Inc.
Phone: 646-277-1282
Email: Stephanie.Carrington@icrinc.com